Advertisement
Research Article

Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy

  • Jeffrey A Johnson mail,

    To whom correspondence should be addressed. E-mail: JJohnson1@cdc.gov

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Jin-Fen Li,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Xierong Wei,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Jonathan Lipscomb,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • David Irlbeck,

    Affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • Charles Craig,

    Affiliation: GlaxoSmithKline, Stevenage, United Kingdom

    X
  • Amanda Smith,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Diane E Bennett,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Michael Monsour,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Paul Sandstrom,

    Affiliation: National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, Ontario, Canada

    X
  • E. Randall Lanier,

    Affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • Walid Heneine

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Published: July 29, 2008
  • DOI: 10.1371/journal.pmed.0050158

Reader Comments (1)

Post a new comment on this article

Similar paper not quoted

Posted by plosmedicine on 31 Mar 2009 at 00:28 GMT

Author: Esteban Domingo
Position: Professor
Institution: Centro de Biología Molecular
E-mail: edomingo@cbm.uam.es
Submitted Date: August 05, 2008
Published Date: August 6, 2008
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

Dear Dr. Johnson: In connection with your article in PLoS Medicine, vol. 5, issue 7, e158 (Johnson et al.) I must point to you that a paper with similar (or the same) conclusions was published in 1995 by Nájera et al. (J. Virol. 69: 23- 31, 1995). This paper should have been discussed and quoted in your article, and I would appreciate that you do so in future articles and reviews. Thank you. Sincerely, Esteban Domingo.

No competing interests declared.